Back

FDA Approves AbbVie’s Juvmo for Parkinson’s Disease Treatment

lite News Desk 2 min read

At a glance

  • The FDA approved Juvmo (tavapadon) for adult Parkinson’s patients on September 25, 2026.
  • Juvmo is described as the first selective D1/D5 dopamine receptor agonist for this condition.
  • AbbVie acquired tavapadon through its 2023 purchase of Cerevel Therapeutics.

The U.S. Food and Drug Administration granted approval to AbbVie’s drug Juvmo, also known as tavapadon, for use in adults with Parkinson’s disease on September 25, 2026. This regulatory decision introduces a new treatment option for individuals diagnosed with Parkinson’s disease.

AbbVie stated that Juvmo is the first and only selective D1/D5 dopamine receptor agonist available for adults with this neurological condition. The company announced the approval shortly after the FDA’s decision, highlighting the drug’s unique mechanism among current therapies.

The FDA’s approval of Juvmo was based on results from the Phase 3 TEMPO clinical trials. According to AbbVie, these studies showed improvements in motor function and increased periods of “on” time without troublesome dyskinesia, along with a favorable safety profile for the medication.

AbbVie obtained the rights to tavapadon through its acquisition of Cerevel Therapeutics in 2023. This acquisition allowed AbbVie to add the drug to its portfolio and advance its development for Parkinson’s disease treatment.

What the numbers show

  • FDA approval date: September 25, 2026.
  • Juvmo is indicated for adults with Parkinson’s disease.
  • AbbVie acquired tavapadon in 2023.

The approval of Juvmo follows the completion of late-stage clinical trials that evaluated its effects on motor symptoms in Parkinson’s patients. AbbVie reported that these trials provided evidence supporting the drug’s efficacy and safety for adult use.

Juvmo’s classification as a selective D1/D5 dopamine receptor agonist distinguishes it from other medications currently approved for Parkinson’s disease. AbbVie emphasized this aspect in its public statements about the drug’s regulatory approval.

The FDA’s decision adds a new option for clinicians treating adult patients with Parkinson’s disease. The agency published the approval on its official list of novel drug approvals for 2026.

* This article is based on publicly available information at the time of writing.

More from Health & Biotech

  1. The FDA has approved Pasatru for treating heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva, according to the regulator.

  2. A panel voted 10-0 to endorse the Galleri test for detecting multiple cancers through a single blood sample, according to the regulator.

  3. The FDA approved Lyrfigtu for advanced cholangiocarcinoma on September 23, 2026, targeting FGFR2-altered cases in adults, according to reports.

  4. A study found 76% of public health leaders reported harassment post-pandemic. Female officials faced higher rates, according to researchers.

  5. A workshop on testosterone therapy for menopausal women occurred on September 17, 2026. Public input was invited, according to the regulator.